Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Hereditary Cancer Testing Market Size And Revenue Forecast Through 2030
The market for hereditary cancer testing has experienced substantial expansion lately. Projections indicate it will advance from $4.75 billion in 2025 to $5.3 billion in 2026, reflecting a compound annual growth rate of 11.6%. Factors contributing to this growth during the preceding period included heightened public understanding of hereditary cancer dangers, the advent of next-generation sequencing technologies, the broadening of diagnostic lab infrastructures, increased doctor referrals for genetic screening, and the proliferation of personalized risk evaluation frameworks.
The market for hereditary cancer testing is poised for substantial expansion over the coming years, projected to reach $8.02 billion by the year 2030, driven by a compound annual growth rate of 10.9%. This anticipated surge is fueled by several key factors, including the broadening scope of population-wide genetic screening, the escalating utilization of artificial intelligence in genomic analysis, a greater emphasis on preventative oncology strategies, heightened demand for affordable testing options, and strengthened regulatory backing for genetic diagnostic tools. Furthermore, significant trends shaping the forecast period encompass a growing preference for multi-gene panel testing, an increasing need for early detection of cancer predispositions, the wider application of sophisticated genetic sequencing technologies, the proliferation of preventive testing programs, and a more integrated approach to clinical decision support systems.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8121&type=smp
Hereditary Cancer Testing Market Growth Drivers: What Factors Are Accelerating Expansion?
The growing incidence of cancer is anticipated to be a primary driver for the market of hereditary cancer testing. Cancer, stemming from the uncontrolled proliferation and spread of aberrant cells, disrupts the body’s normal cellular regulation. Hereditary cancer testing is instrumental in managing this escalating health challenge by pinpointing individuals who possess genetic vulnerabilities to specific cancers. Through the evaluation of inherited genetic alterations and family history, this diagnostic approach identifies those at elevated risk, thereby facilitating timely medical interventions, tailored therapeutic strategies, and preventative actions. As an illustration, Australian Institute of Health and Welfare data from July 2024 indicated a rise in cancer diagnoses in Australia from 160,570 in 2022 to 164,694 in 2023, underscoring a significant year-over-year increase and signifying the increasing prevalence of the disease within the nation. Consequently, the expanding cancer burden is fueling the expansion of the hereditary cancer testing market.
Hereditary Cancer Testing Market Segment Breakdown: Which Categories Generate The Most Revenue?
The hereditary cancer testing market covered in this report is segmented –
1) By Test Type: Multi Panel Test, Single-Site Genetic Test
2) By Indication: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications
3) By End user: Hospital, Clinics, Diagnostic Centers
Subsegments:
1) By Multi Panel Test: Comprehensive Genetic Panels, Targeted Gene Panels
2) By Single-Site Genetic Test: Specific Gene Testing, Familial Mutation Testing
Hereditary Cancer Testing Market Trends: What Is Shaping Future Industry Growth?
The hereditary cancer testing market is characterized by leading companies concentrating on cutting-edge technologies, including molecular diagnostic tumor testing, aimed at boosting precision, optimizing patient results, and tailoring treatment plans. This type of testing scrutinizes the genetic and molecular makeup of a tumor to guide therapeutic choices and forecast prognoses. As an illustration, in February of 2023, Chubb Business Services India Private Limited, a global insurance provider headquartered in India, introduced Cancer Advocate Plus. This initiative incorporates genetic testing designed to pinpoint hereditary genes linked to an elevated risk of developing cancer, thereby enabling individuals to grasp their predisposition to different cancers and fostering an environment of early detection and customized healthcare approaches.
Hereditary Cancer Testing Market Key Players And Strategic Industry Positioning
Major companies operating in the hereditary cancer testing market are Centogene NV, Ambry Genetics Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics Inc., Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health Inc., CooperSurgical Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes Ltd., Associated Regional and University Pathologists Inc., 4baseCare, Biocartis Group NV, F. Hoffmann-La Roche AG, Medgenome Pvt. Ltd., Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies PLC, PerkinElmer Inc.
Access The Complete Hereditary Cancer Testing Market Report:
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Hereditary Cancer Testing Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the hereditary cancer testing market in 2025. The regions covered in the hereditary cancer testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
